Filipa Lynce

Aug 31, 2024 | acsjournals.onlinelibrary.wiley.com | Stuart Lipsitz |Laura S Dominici |Filipa Lynce |Christina A. Minami

CONFLICT OF INTEREST STATEMENT Ko Un Park reports travel support and support for other professional activities from OncLive outside the submitted work. Laura S. Dominici reports support for professional activities from PeerView outside the submitted work.

Aug 9, 2024 | onclive.com | Filipa Lynce

CommentaryVideoAugust 9, 2024Author(s):Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer. Filipa Lynce, MD, senior physician, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School, discusses 2 ongoing clinical trials investigating novel therapeutic combinations for the treatment of patients with inflammatory breast cancer.

May 10, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-46961-x, published online 27 March 2024The original version of the article file contained some inaccuracies in the main text. To avoid misinterpretation of the findings, the following corrections have now been made in the revised PDF and HTML versions of the article file. Abstract.

Apr 3, 2024 | nature.com | Paolo Tarantino |Ana C. Garrido-Castro |Filipa Lynce |Sara M. Tolaney

AbstractTo evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively).

Mar 26, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

AbstractChemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint).